Legend Biotech Corporation (LEGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 47.12 |
| Open | 47.12 |
| Bid | 46.06 x 100 |
| Ask | 46.18 x 100 |
| Day's range | 45.68 - 47.30 |
| 52-week range | 45.68 - 77.32 |
| Volume | |
| Avg. volume | 1,003,623 |
| Market cap | 8.402B |
| Beta (5Y monthly) | 0.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.94 |
| Earnings date | 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 86.16 |
Business WireLegend Biotech to Host Investor Conference Call on First Quarter 2024 Results
SOMERSET, N.J., April 11, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.
ZacksFDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
ZacksWhy Legend Biotech (LEGN) Stock Might be a Great Pick
Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
© 2024 Yahoo. All rights reserved.